BMJ14h
POS1470 POOR LONG-TERM OUTCOMES AND SUBSTANTIAL UNMET NEEDS IN EUROPEAN PATIENTS WITH LUPUS NEPHRITIS
1 University Hospitals of Strasbourg, French National Reference Center for Rare Auto-immune Diseases (RESO), Department of Rheumatology, Strasbourg, France 2 Maple Health Group, LLC, New York, United ...
BMJ23h
AB0502 CELLULAR AND PROTEOMIC CHANGES FOLLOWING ADMINISTRATION OF PERESOLIMAB, IN A PHASE 2A TRIAL IN RHEUMATOID ARTHRITIS
Background: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). Peresolimab demonstrated superiority to placebo in Disease ...
BMJ1d
AB1192 PREVALENCE, RISK FACTORS, AND OUTCOMES OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN CHINESE: A MULTI-CENTRED COHORT STUDY
1 Alice Ho Miu Ling Nethersole Hospital, Department of Medicine, Tai Po, Hong Kong (SAR) 2 The Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Medicine and Therapeutics, ...
BMJ2d
Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration
Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...
BMJ2d
When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
Objective: To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to ...
BMJ2d
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ3d
POS0819 ANTI-CD19 CAR T CELL THERAPY IN SYSTEMIC SCLEROSIS – EXPERIENCES FROM TUEBINGEN IN 3 PATIENTS
1 University Hospital Tuebingen, Center for Interdisciplinary Rheumatology, Immunology and Autoimmune Diseases (INDIRA) and Department for Internal Medicine II (Hematology, Oncology, Rheumatology and ...
BMJ3d
POS0803 VUNAKIZUMAB IN ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, SEAMLESS, PHASE 2/3 STUDY
3 The First Affiliated Hospital of Guangxi Medical University, NanNing, China 4 The Second Affiliated Hospital of Guangxi Medical University, NanNing, China 5 The First Affiliated Hospital of ...
BMJ4d
Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis
Objectives Although T cells have been implicated in the pathogenesis of systemic sclerosis (SSc), a comprehensive study of T-cell-mediated immune responses in the affected skin of patients with ...
BMJ5d
Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data
Objective To assess the risk of hypersensitivity reactions (HSRs) with allopurinol and febuxostat in a population-based study. Methods We used the 5% Medicare beneficiary sample (≥65 years) from 2006 ...
BMJ6d
AB0132 AFIMETORAN (BMS-986256), AN EQUIPOTENT TLR7/8 ANTAGONIST, DEMONSTRATES STEROID-SPARING EFFECTS IN A LUPUS MOUSE MODEL
2 Biocon Bristol Myers Squibb Research Center, Discovery Biology, Bangalore, India 3 Bristol Myers Squibb, Medicinal Chemistry, Lawrenceville, United States of America 4 Bristol Myers Squibb, ...
BMJ6d
Wnt16 attenuates osteoarthritis progression through a PCP/JNK-mTORC1-PTHrP cascade
Correspondence to Professor Ling Qin, Prince of Wales Hospital, Hong Kong, China; lingqin{at}cuhk.edu.hk; Professor Kingston King-lun Mak, Joint Center for Musculoskeletal Research, Guangzhou ...